The coronavirus pandemic has affected economies and industries around the world, and while things seem to be getting back on track in some sectors, frontline workers still remain the most affected by COVID-19, which has caused millions to die.
Data from a poll conducted by EClinicalMedicine, the Lancet, shows that almost 50% of healthcare workers suffered burnouts, nearly 45% suffered work overload, more than 35% admitted to being depressed or feeling anxiety, and more than 60% feared that they had been exposed to the disease and/or could be transmitting it.
The survey, which had more than 20,000 healthcare workers from more than 40 organizations participating, was carried out between May and October of last year.
The University of Washington and Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF), a biotech firm that is focused on psychedelics, will be co-financing a placebo-controlled, randomized clinical trial of psilocybin-assisted psychotherapy for healthcare workers who are experiencing distress associated with the coronavirus. Their objective is to help boost the situations of frontline workers.
The study will assess the effectiveness of psilocybin-assisted therapy in treating symptoms of post-traumatic stress, burnout, anxiety and depression in frontline nurses, doctors and other healthcare professionals. Dr. Anthony Back will be the lead of the study, which will take place in Seattle, Washington. The city was severely impacted by coronavirus during the onset of the pandemic.
To back the cause, Cybin and researchers Bill Brennan and Alex Belser have designed a psychotherapy model dubbed EMBARK, which can be modified to address various populations and clinical indications. The researchers explained that the transdiagnostic model was a ground-breaking invention that integrated different clinical approaches to encourage supportive healing with psychedelics.
Back also noted that the collaboration between Cybin and the University of Washington to conduct the study would help move the field forward, adding that this research project was the first step towards a rewarding future.
In addition, Cybin’s chief clinical officer Dr. Alex Belser commented that the country’s clinicians, nurses and doctors had carried the burden of the coronavirus by taking care of individuals who were sick during the pandemic and were now experiencing high levels of burnout, depression and anxiety. Belser asserted that it was now time to take care of the caregivers, which was why the company was financing the study, which would evaluate the effectiveness of psychedelic medicine when utilized with EMBARK, to help healthcare workers recover from the distress associated with the coronavirus.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.